When it comes to pancreatic cancer, early detection is key. And while there is not currently a reliable test available, some of the world’s leading researchers are looking to change that.
Each year, Rolfe Pancreatic Cancer Foundation awards a number of grants, often funding projects or programs that are novel and not duplicative of current initiatives. In addition, Rolfe encourages the sharing of information and resources between the scientists, and among institutions pursuing pancreatic cancer research for the greatest opportunity for advancement.
In our final Wellness Wednesday of the year, we’ll showcase the impact of your donations. Drs. Chuan He, Marc Bissonnette and Kay Macleod will share the latest breakthroughs their research has uncovered, including:
- An epigenetic blood test for pancreatic cancer
- What the gene BNIP3 tells us about pancreatic cancer progression
- A look at what’s ahead in pancreatic cancer research
Featuring: Dr. Chuan He Ph.D., Dr. Marc Bissonnette M.D., and Dr. Kay Macleod Ph.D.
A special thank you to our Wellness Wednesday partner WEX - Wolverine Execution Services and the Bellick Family.
About the speakers:
Dr. Chuan He
Chuan He, Ph.D. is the current John T. Wilson Distinguished Professor at the University of Chicago and an Investigator at the Howard Hughes Medical Institute (HHMI) since 2014.
Dr. Marc Bissonnette
Marc Bissonnette is an Associate Professor in the Department of Medicine, Section of Gastroenterology at the University of Chicago. He is a member of the University of Chicago Comprehensive Cancer Center.
Dr. Kay Macleod
Dr. Macleod is a graduate of the University of Edinburgh, Scotland (B.Sc. Hons) and obtained her Ph.D. from the Beatson Institute for Cancer Research at the University of Glasgow, Scotland. Dr. Macleod's research is focused on understanding the role of mitophagy and mitochondrial dysfunction in cancer.